Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 211 AL 225

Intravenous immunoglobulin and Alzheimer's disease: what now?

Loeffler DA.

J Neuroinflammation. 2013 Jun 5;10:70. doi: 10.1186/1742-2094-10-70.

Testosterone effect on brain metabolism in elderly patients with Alzheimer's disease: comparing two cases at different disease stages

Tan RS.

Aging Clin Exp Res. 2013 Jun;25(3):343-7. doi: 10.1007/s40520-013-0049-2. Epub 2013 May 17.

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response

Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R.

BMC Geriatr. 2013 Jun 6;13:56. doi: 10.1186/1471-2318-13-56.

Effects of ramelteon on refractory behavioral and psychological symptoms of dementia in Alzheimer disease

Asano M, Ishitobi M, Tanaka Y, Wada Y.

J Clin Psychopharmacol. 2013 Aug;33(4):579-81. doi: 10.1097/JCP.0b013e3182946702.

Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease

Rive B, Gauthier S, Costello S, Marre C, François C.

CNS Drugs. 2013 Jul;27(7):573-82. doi: 10.1007/s40263-013-0074-x.

Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database

Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R.

J Alzheimers Dis. 2013;37(1):173-83. doi: 10.3233/JAD-130575.

Current status of PET-imaging probes of β-amyloid plaques

Koo J, Byun Y.

Arch Pharm Res. 2013 Oct;36(10):1178-84. doi: 10.1007/s12272-013-0193-4. Epub 2013 Jul 1.

Personalized medicine in Alzheimer's disease and depression

Souslova T, Marple TC, Spiekerman AM, Mohammad AA.

Contemp Clin Trials. 2013 Nov;36(2):616-23. doi: 10.1016/j.cct.2013.06.012. Epub 2013 Jun 29.

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M.

CNS Neurosci Ther. 2013 Oct;19(10):745-52. doi: 10.1111/cns.12158. Epub 2013 Aug 7.

Novel disease-modifying therapeutics for the treatment of Alzheimer's disease

Léger GC, Massoud F.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):423-42. doi: 10.1586/17512433.2013.811237.

Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria

Carrillo MC, Dean RA, Nicolas F, Miller DS, Berman R, Khachaturian Z, Bain LJ, Schindler R, Knopman D; Alzheimer's Association Research Roundtable.

Alzheimers Dement. 2013 Sep;9(5):594-601. doi: 10.1016/j.jalz.2013.05.1762.

Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial

Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer JE, ADMET Investigators.

J Clin Psychiatry. 2013 Aug;74(8):810-6. doi: 10.4088/JCP.12m08099.

Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study

Schmitt FA, Saxton J, Ferris SH, Mackell J, Sun Y.

Int J Clin Pract. 2013 Oct;67(10):1050-6. doi: 10.1111/ijcp.12188.

[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 2. Dementia]

Moritoyo T.

Nihon Naika Gakkai Zasshi. 2013 Aug 10;102(8):1916-22. doi: 10.2169/naika.102.1916.

Effect of reinforcing kidney-essence, removing phlegm, and promoting mental therapy on treating Alzheimer's disease

Liu P, Kong M, Liu S, Chen G, Wang P.

J Tradit Chin Med. 2013 Aug;33(4):449-54. doi: 10.1016/s0254-6272(13)60147-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias